Home » Stocks » TMCI

Treace Medical Concepts, Inc. (TMCI)

Stock Price: $27.03 USD -0.04 (-0.15%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 1.41B
Revenue (ttm) 57.37M
Net Income (ttm) n/a
Shares Out 52.34M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $27.03
Previous Close $27.07
Change ($) -0.04
Change (%) -0.15%
Day's Open 27.13
Day's Range 26.04 - 28.01
Day's Volume 94,103
52-Week Range 24.25 - 37.17

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PONTE VEDRA, Fla., May 25, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm s...

2 months ago - GlobeNewsWire

Medical device company Treace Medical Concepts Inc (NASDAQ: TMCI) has announced interim results from the ALIGN3D clinical study, a post-market 5-year study designed to evaluate outcomes of Lapiplasty 3D...

2 months ago - Benzinga

PONTE VEDRA, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgica...

2 months ago - GlobeNewsWire

PONTE VEDRA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgi...

2 months ago - GlobeNewsWire

PONTE VEDRA, Fla., May 12, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgica...

2 months ago - GlobeNewsWire

PONTE VEDRA, Fla., April 22, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgi...

3 months ago - GlobeNewsWire

PONTE VEDRA, Fla., April 22, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgi...

3 months ago - GlobeNewsWire

Ponte Vedra-based company plans to reach the market this week.

3 months ago - Jax Daily Record

Treace Medical Concepts, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About TMCI

Treace Medical Concepts is a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions). We have pioneered our proprietary Lapiplasty 3D Bunion Correction System – a combination of novel instruments, implants and surgical methods designed to improve the inconsistent clinical outcomes of traditional approaches to bunion surgery. Although bunions are deformities typically caused by an unstable joint in the middle of the foot that leads to a three-dimensiona... [Read more...]

Industry
Medical Devices
IPO Date
Apr 23, 2021
CEO
John T. Treace
Employees
133
Stock Exchange
NASDAQ
Ticker Symbol
TMCI
Full Company Profile

Financial Performance

In 2020, TMCI's revenue was $57.37 million, an increase of 45.54% compared to the previous year's $39.42 million. Losses were -$3.67 million, -14.00% less than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for TMCI is 35.67, which is an increase of 31.96% from the latest price.

Price Target
$35.67
(31.96% upside)